Toledo Community Oncology Program Logo

Member Login Phone: 419-843-6147
Email: info@tcop.info

Trial Search

TCOP conducts a variety of clinical trials every year. In fact, there are over 100 trials running at any given time, each specifically focusing on a particular type of cancer research. To find out if there are current trials running, addressing a specific form of cancer, click on a cancer type in the list below.


  • Brain
    • Glioblastoma
      • N0877
        • Phase I Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (Opened to Phase II - 9/14/11)
      • N0872
        • Phase I/II Study of Dasatinib/Bevacizumab in Recurrent Glioblastoma (Study 2). (Opened to Phase II - 9/14/11)
      • A221101
        • A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiform
    • Glioma
      • N0577 - (Suspended)
        • Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone vs. Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
    • Translational Study
      • NCCTG- 94-72-52
        • Diagnostic and Prognostic Markers in High-Grade Glioma. (study title changed 5/10/06 - addendum 5)
  • Breast
    • Adjuvant
      • NSABP B-47
        • Randomized Phase 3 Trial of Adjuvant Therapy comparing Chemotherapy Alone (Six cycles of Docetaxel Plus Cyclophosphamide or Four cycles of Doxorubicin Plus Cyclophosphamide Followed by Weeekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2 Low Invasive Breast Cancer
      • S1007
        • Phase III, Randomized Clinical trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor Positive and HER2 Negative Breast Cancer with Recurrence Score of 25 or less.
    • Breast
      • RTOG-1110
        • Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2 Positive Breast Cancer - A Colloborative Study of RTOG and KROG
    • Cancer Control
      • HLMCC 0806
        • Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving Neo-Adjuvant Chemotherapy with Trastuzumab (Herceptin)
      • CALGB-40903
        • Phase II Study of Neoadjuvant Letrozole for Post-Menopausal Women with Estrogen Receptor Positive Ductal Carcinoma In Situ (DCIS)
    • HER2 Negative
      • NSABP B-49
        • A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
    • HER2+
      • NSABP B-43-CC
        • Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2+ Ductal Carcinoma In Situ Resected by Lumpectomy
      • RTOG-1119
        • Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG
    • Local Recurrence
      • RTOG-1014
        • Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-irradiation for Local Recurrence of Breast Carcinoma
    • Metastatic Breast
      • E3108
        • Phase III Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
      • E2108
        • Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
      • 8129 - (Suspended)
        • Phase I/II Trial of IMC-A12 in Combination with Temsirolimus in Patients with Metastatic Breast Cancer
    • Metastatic Triple Negative
      • N093B - (Suspended)
        • Phase I/II Study of Panobinostat (LBH589) and Letrozol in Patients with Triple Negative Metastatic Breast Cancer (Industry Funds -Venipuncture $19.78 per procedure – Maximum 3 per Patient2 $59.34)
  • Cancer Control
    • Cancer Control
      • S0702
        • A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
      • N07C4
        • Version 10/17/12. Randomized Phase II Trial Evaluating Two Non-Pharmacologic Interventiosn in Cancer Survivors for the Treatment of Sleep-Wake Disturbances
      • PACCT-1 Ancillary
        • Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Tretament (TAILORx Trial)
  • Gastrointestinal
    • Colon
      • CALGB-80702
        • Phase III Trial of 6 vs. 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients wtih Resected Stage III Colon Cancer
    • Colorectal
      • E7208 - (Suspended)
        • Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-angiogenic Antibody, Ramucirumab (IMC-1121B) in Advanced, K-Rase Wild Type Colorectal Cancer Following Progression on Bevacizumab Containing Chemotherapy
      • S0820
        • Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
    • Gastroesophageal
      • RTOG-1010
        • Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
      • CALGB-80803
        • Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
      • S1201
        • Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Cancer
    • Hepatocellular
      • CALGB-80802
        • Phase III Randomized Study of Sorafenib (IIND 69896, NSC 724772) plus Doxorubicin versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)
      • E1208
        • Phase III Randomized, double-Blind Trial of Chemoemobolization With or Without Sorafenib in unresectable Hepatocellular Carcinoma in Patients With or Without Vascular Invasion
    • Pancreas
      • RTOG-0848
        • Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancrease Adenocarcinoma
      • S1115
        • Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate and MK-2206 vs. MFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy
      • E2211
        • A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
    • Small Bowel
      • N0543
        • Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
  • Genitourinary
    • Prostate
      • RTOG-0534
        • Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy QOL closed 4/11/2012
      • RTOG-0526
        • Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarccinoma Following External Beam Radiotherapy
      • RTOG-0815
        • A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate Risk Prostate Cancer----QOL Closed 4/11/2912
      • E2809
        • A Phase 2, Randomized Study of MK-2206 Bicalutamide Combination in patients with Rising PSA at High-Risk of Progression After Primary Therapy
      • RTOG-0924
        • Androgen Deprivatino Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
      • RTOG-1115
        • Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
      • S1216
        • Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
    • Renal Cell
      • S0931
        • Phase III Study: Everolimus for Renal Cancer Ensuing Surgical Therapy
    • Transitional Cell
      • CALGB-90601
        • Randomized, Double-Blinded, Phase III Study Comparign Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
  • GYN
    • Cervical
      • RTOG-0724
        • Version 12/29/10. Phase II Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early Stage Cervical Carcinoma Following Radical Hysterectomy
  • Head and Neck
    • Head/Neck
      • RTOG-0920
        • A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
    • Oropharynx
      • RTOG-1016
        • Phase III Trial of Radiotherapy Plus Cetuximab vs. Chemoradiotherapy in HPV-Associated Oropharynx Cancer (QOL closed 4/10/2013)
    • Salivary Gland
      • RTOG-1008
        • Randomized Phase II Study of Concurrent Radiation and Chemotherapy vs. Radiation Alone in Resected High Risk Malignancy Salivary Gland Tumors
  • Hematology
    • Anemia
      • E2905 - (Suspended)
        • Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlamid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low or Intermediate -1 Risk MDS and Symptomatic Anemia
    • Follicular Lymphoma
      • E2408
        • A 3-Arm Randomized Phase 2 Trial Of Bendamustine-Rituximab Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
      • CALGB-50904
        • Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lympoma
      • E2408-QOL
        • A 3-Arm Randomized Phase 2 Trial Of Bendamustine-Rituximab Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
    • Hematology
      • E3903
        • Ancillary Laboratory Protocol for the Collection of Diagnostic Material of Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders
      • S1117
        • Randomized Phase II Study of Azacitidine in Combinatino with Lenalidomide vs. Azacitine Alone vs. Azacitidine in Combination with Vorinastat for Higher-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia
    • Hodgkins
      • E2410
        • Phase II Trial of Response-Adapted therapy Based on Positron Emission Tomography for Bulky State I and II Classical Hodgkin Lymphoma
    • Mantle Cell Lymphoma
      • S1106
        • Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. R-Bendamustine Induction Followed by Conslidation with an Autologous Stem Cell Transplant for Patients 65 yrs. or less with Previously Untreated Mantle Cell Lyphoma
    • Multiple Myeloma
      • E3A05
        • Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Multiple Myeloma and Other Plasma Cell Disorders
  • Lung
    • Esophagitis Pain
      • RTOG-1012
        • Phase II Randomized Trial of Prophylactic Manuika Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer
    • Non-Small Cell
      • E1505
        • Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage Ib-IIIA Non-Small Cell Lung Cancer
      • CALGB-30607
        • Randomized, Phase III, Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination chemotherapy in Advanced, Stage IIIB/IV NSCL
      • RTOG-0813
        • Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
      • S0819
        • Randomized Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer
      • E5508
        • Randomized Phase III Study of Maintenance therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer
      • CALGB-30801
        • Randomized Phase III double-Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
      • E6508
        • Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
      • RTOG-0839
        • Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer.
      • CALGB-30801 PRE
        • Randomized Phase III double-Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
      • E1512
        • A randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
    • Small Cell
      • RTOG-0937
        • Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer ((ED-SCLC)
  • Melanoma
    • Melanoma
      • N0879
        • Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, With or Without Everolimus for Therapy of Metastatic Malignant Melanoma
      • E1609
        • Phase III Study of Adjuvant Ipilimumab anti-CTLA4 Therapy vs. High Dose Interferon Alpha 2B for Resected High-Risk Melanoma
      • E1609-QOL
        • Phase III Study of Adjuvant Ipilimumab anti-CTLA4 Therapy vs. High Dose Interferon Alpha 2B for Resected High-Risk Melanoma
      • E3611
        • A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination with High Dose Interferon-α in Advanced Melanoma
  • Pharmaceutical - Limited Sites.
    • Breast
      • BO25126
        • Prospective, Randomized, Multi-Center, Multinational, Double-blind Placebo Controlled Comparison of Chemotherapy Plus Trastuzumab and Placebo Given for a Total of One Year vs. Chemotherapy Plus Trastuzumab and Pertuzumab given for a Total of One Year as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer
    • Colorectal
      • ML25710
        • Randomized Phase II Study of Bevacizumab/mFIOLFOX6 vs. Bevacizumab/FOLFIRI with Biomarker Stratification in Patients with Previously Untreated Metastatic Colorectal Cancer (MAVERICC)
      • BTCL-PGG-CRC-1031
        • Phase III Open-Label Randomzied, Multicenter Study of Imprime PGG in Combination with Erbitux in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer
    • Hematology
      • PIX306
        • Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine and Rituximab in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma who have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
    • Lung
      • MO22097
        • Open-Label, Randomized, Phase IIIB Trial Evaluating the Efficacy and Safety of Standard of Care +/- continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer After First-Line Treatment with Bevacizumab Plus a Platinum Doublet-containing Chemotherapy
    • Vaccine Trial
      • V212-011
        • Randomized, Placebo Controlled Trial of An Inactivated Zoster Vaccine for Prevention of Zoster in Patients with Hematologic Malignancy or Solid Tumor
  • Sarcoma
    • Sarcoma
      • A091102
        • A Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
  • Unspecified
    • Metastatic
      • RTOG-0631
        • Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis
    • Patient Satisaction Survey
      • N0392
        • Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials (1 page information consent approved IRB 11/14/07)

Find Oncology Partner Links

Partner Links

Prevention

Prevention

Donations

Donations